SCHEMBL18896239

SCHEMBL18896239

Cc1cc(C(=O)NC(C)C)on1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
HCAR2 Q8TDS4 1/20 0.56
VHL P40337 1/20 0.55
KMT2A Q03164 5/20 0.52
MEN1 O00255 3/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
TP53 P04637 2/20 0.49
GLA P06280 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
USP2 O75604 1/20 0.48
ALOX12 P18054 1/20 0.47
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SGPL1 O95470 1/20 0.44
CHRNA4 P43681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19197700 0.81 NPC1 (0.42) POLBVHLKMT2AMEN1NPC1
SCHEMBL4034128 0.79 HCAR2 (0.62) POLBHCAR2VHLKMT2AMEN1
SCHEMBL10274852 0.79 POLB (0.64) POLBHCAR2KMT2AMEN1NPC1
SCHEMBL18896241 0.79 PSMB8 (0.51) POLBKMT2AMEN1NPC1RAB9A
SCHEMBL19886210 0.78 ALDH1A1 (0.49) VHLKMT2AMEN1NPC1RAB9A
SCHEMBL7362697 0.78 POLB (0.67) POLBHCAR2VHLKMT2AMEN1
SCHEMBL8023869 0.76 HCAR2 (0.62) POLBHCAR2VHLKMT2AMEN1
SCHEMBL10274854 0.75 POLB (0.78) POLBHCAR2KMT2AMEN1NPC1
SCHEMBL3740701 0.75 POLB (0.67) POLBHCAR2KMT2AMEN1NPC1
SCHEMBL21467381 0.75 POLB (0.57) POLBHCAR2KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-10966967-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-06 US disclosed
US-20200281905-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-09-10 US disclosed
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-30 US disclosed
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
US-9663466-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314346-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 POLB 3400/4885HCAR2 652/4885VHL 3664/4885
US-20210161869-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 POLB 3400/4885HCAR2 652/4885VHL 3664/4885
US-10966967-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 POLB 3400/4885HCAR2 652/4885VHL 3664/4885
US-10695328-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors DGAT2, MGAT2, MGAT1 POLB 3400/4885HCAR2 652/4885VHL 3664/4885
US-20200281905-A1 ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS DGAT2, MGAT2, MGAT1 POLB 3400/4885HCAR2 652/4885VHL 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.